Source: Shutterstock/Africa Studio

Innovative test

Diagnosis of bacterial vaginosis

Bacterial vaginosis (BV) is a common infectious disorder that affects millions of women worldwide. Women of all ages are at risk for BV and its complications, which include a greater susceptibility to sexually transmitted infections (STIs) such as herpes simplex virus and HIV.

If left undetected and untreated, BV can increase a woman's risk of upper genital tract infections such as pelvic inflammatory disease, salpingitis, and endometriosis, which may contribute to infertility. BV is a particularly serious problem for pregnant women and their unborn babies, and is associated with preterm birth and premature rupture of membranes, which is why screening for BV is increasingly considered in pregnant women.

Visit Sekisui Diagnostics at ECCMID 2018:

Booth #33A

Clinical Information

BV is the most common cause of infectious vaginitis. Normal vaginal flora is dominated by lactobacilli. In BV, the lactobacilli are replaced by mainly anaerobic microorganisms such as Gardenerella vaginalis, Bacteroides spp., Prevotella spp., and Mobiluncus spp. These bacterial pathogens responsible for BV infection produce sialidases, which are enzymes that cleave sialic residues in oligosaccharides, glycoproteins, and glycolipids. Studies have shown increased sialidase activity in the vaginal fluid of women who have BV.1

Diagnostic Methods

Diagnostic testing for BV should be accurate, timely, and cost efficient. Available testing approaches each have advantages and limitations. Current methods differ mainly in their sensitivity, turnaround time to results, ease of use, cost, and their ability to be performed in a variety of treatment settings, including a physician's office, clinic, or other point-of-care setting. The four main methods for diagnosing BV are Amsel Criteria, Gram Stain with Nugent Score, Molecular testing, and OSOM® BVBlue®.


Click here to learn more about the




Requires the assessment of 4 different criteria. If 3 out of the 4 criteria are present, a diagnosis of BV can be made:

  1. Thin gray/white vaginal discharge
  2. Vaginal pH > 4.5
  3. Positive WHIFF test (amines)
  4. Presence of >20% Clue cells on wet mount

A disadvantage of this method would be the need for a microscope and trained technologist.


(considered Gold Standard)

This method is an accurate method that involves quantifying the bacteria in a stained vaginal smear and scoring the sample, with a score >7 considered to be positive for BV. This method can be labor intensive, requires a microscope, and advanced laboratory skills. 


Molecular methods detect DNA sequences from microorganisms associated with BV. These methods are very accurate. However, this type of testing may not be suitable for clinics due to expense and technical requirements. It is also not amenable to a test-and-treat strategy due to turnaround time. 


OSOM® BVBlue® is a rapid test that detects sialidase activity in a vaginal fluid sample. This assay is designed for use in a clinical setting and allows for a test-and-treat approach. 


OSOM® BVBlue® detects elevated vaginal fluid sialidase activity, from the following bacterial pathogens Gardnerella, Bacteroides, Prevotella and Mobiluncus.

OSOM® BVBlue® is easy to perform, requiring no special skills, training, or instrumentation. The test protocol is rapid, allowing the clinician to begin appropriate treatment in the same patient visit. This potentially accelerates the time to diagnosis. It also avoids any delay in initiation of treatment and minimizes the risk of patients not returning for follow-up.

Diagnosis of bacterial vaginosis
Source: Sekisui Diagnostics


The risks to pregnant women from BV include increased likelihood of preterm birth and low birth weight babies, which can present important public health and economic concerns. The goal of a BV diagnostic test is to accurately and rapidly detect infection by the organisms causing BV, and thereby enable initiation of appropriate treatment as soon as possible. OSOM® BVBlue® is an easy-to-use, cost-efficient, point-of-care diagnostic test that provides rapid results, allowing a test-and-treat approach to the management of patients with BV.


1. McGregor JA, French JI, Jones W, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: Results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994; 170(4): 1048-1059.

Source: Sekisui Diagnostics


Read all latest stories

Related articles


Women's health

Benign gynaecology specialist centres are needed

The recently opened Uterine Repair Center (URC) in VUmc (Amsterdam) serves women suffering non-cancerous gynaecological disorders, such as myomas, adenomyosis (endometriosis of the uterus), niches…


The issue is not over-diagnosis but over-treatment

'We desperately need a ‘no treatment’ trial for DCIS', says Clive Wells, Chairman of the European Working Group on Breast Cancer Pathology, and London Regional Co-ordinator for the United…


Coronavirus infection response

SARS-CoV-2 IgG II antibody test launched in CE Mark countries

Clinical diagnostics company Beckman Coulter launched its Access SARS-CoV-2 IgG II assay in countries accepting the CE Mark. The new Access SARS-CoV-2 IgG II assay quantitatively measures a…

Related products

Image Information Systems – iQ-4VIEW

Mobile RIS/PACS Viewer

Image Information Systems – iQ-4VIEW

IMAGE Information Systems Europe GmbH
i-Solutions Health – LabCentre

LIS, Middleware, POCT

i-Solutions Health – LabCentre

Medat – Laboratory Information System

LIS, Middleware, POCT

Medat – Laboratory Information System

Medat Computer-Systeme GmbH